



## John R. Laird, M.D.

**Philosophy of Care** To provide comprehensive cardiovascular care including preventative approaches, optimal medical care and state of the art, minimally invasive therapies.

**Clinical Interests** Dr. Laird is an internationally renowned interventional cardiologist who has lectured and performed endovascular procedures around the world. He has also been a leader in the development of Drug Coated Balloon for peripheral artery disease. His practice focuses on interventions for carotid artery disease, abdominal and thoracic aortic aneurysmal disease, renal artery disease and peripheral artery disease. Among his many areas of leadership and innovation are the investigation of new stents for carotid and peripheral vascular applications and the development of laser angioplasty. He uses the Excimer laser as a tool for complex peripheral interventions and in limb salvage situations. Dr. Laird is known for innovation, teaching vascular interventions to other physicians, and his role in organizing and conducting clinical trials of new therapies for vascular disease.

**Research/Academic Interests** Dr. Laird's research interests include:

- 1-Innovative approaches to the treatment of peripheral artery disease including new stent designs, drug eluting stents, and drug coated balloons.
- 2-Stent grafts for abdominal and thoracic aneurysms.
- 3-Stem cell therapies for advanced peripheral artery disease.
- 4-New stents for carotid artery disease.

**Title** Medical Director, UC Davis Vascular Center  
Professor of Medicine

**Specialty** [Cardiology](#), [Cardiovascular Medicine](#), Internal Medicine, Interventional Cardiology, Vascular and Endovascular Care

**Department** [Internal Medicine](#)

**Division** Cardiovascular Medicine

**Center/Program Affiliation** [Cardiovascular Services](#)

**Address/Phone** Lawrence J. Ellison Ambulatory Care Center, 4860 Y St. Suite 2820 Sacramento, CA 95817  
**Phone:** 916-734-3800

**Additional Phone** Physician Referrals: 800-4-UCDAVIS (800-482-3284)

**Education** M.D., Albany Medical College, Albany NY 1984



## John R. Laird, M.D.

**Internships** Madigan Army Medical Center, Tacoma WA 1985

**Residency** Madigan Army Medical Center, Tacoma WA 1987

**Fellowships** Walter Reed Army Medical Center, Washington DC 1990

**Board Certifications** American Board of Internal Medicine, 1987

American Board of Internal Medicine, Cardiovascular Disease, 1989

American Board of Internal Medicine, Interventional Cardiology, 1999

**Professional Memberships** American College of Cardiology

American College of Physicians

American Heart Association

International Society of Endovascular Specialists

Society for Cardiac Angiography and Interventions

**Honors and Awards** LIVE (Leader in Vascular Education) Award, VIVA, 2013

**Select Recent Publications** Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, Krishnan P, Scheinert D, Micari A, Cohen D, Wang H, Hasenbank MS, Jaff MR, for the IN.PACT SFA Trial Investigators. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. 24-Month Results of IN.PACT SFA. J Am Coll Cardiol. 2015 Dec 1;66(21): 2329-38.

Laird JR, Singh GD. Drug Coated Balloons as the New Standard of Care for Femoropopliteal In-Stent Restenosis: Fair Assumption? Circulation. J of the Am Heart Assoc. 2015 Dec 8;132(23): 2198-200.

Armstrong EJ, Thiruvoipati T, Tanganyika K, Singh GD, Laird JR. Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis. J of Endovasc Ther. 2015 Aug;22(4):506-513.

Armstrong EJ, Chen DC, Singh GD, Amsterdam EZ, Laird JR. Angiotensin-Converting Enzyme Inhibitors are Associated with Reduced Major Adverse Cardiovascular Events Among Patients with Critical Limb Ischemia. Vasc Med. 2015 Jun;20(3):237-44.



## John R. Laird, M.D.

Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR. Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Artery Disease: 12-Month Results from the IN.PACT SFA Randomized Trial. *Circulation*. 2015 Feb 3;131(5):495-502.

Laird JR, Armstrong EJ. Drug Coated Balloons for Infrapopliteal Disease: Digging Deep to Understand the Impact of a Negative Trial. *J Am Coll Cardiol*. 2014 Oct 14;64(15):1577-9.

Armstrong EJ, Wu J, Singh GD, Ware K, Dawson DL, Pevac WC, Amsterdam EA, Laird JR. Smoking Cessation is Associated With Decreased Mortality and Improved Amputation- Free Survival Among Patients with Symptomatic Peripheral Artery Disease. *J Vasc Surg*. 2014 Dec;60(6):1565-1571.

Singh S, Armstrong EJ, Sherif W, Alvandi B, Westin GG, Singh GD, Amsterdam EA, Laird JR. Association of Elevated Fasting Glucose with Restenosis and Major Adverse Limb Events Among Patients with Diabetes Undergoing Infrapopliteal Balloon Angioplasty. *Vasc Med*. 2014 Jun 17;19(4):307-314.

Armstrong EJ, Laird JR. Treatment of Femoropopliteal In-Stent Restenosis for Patients with Diabetes: Do We Have an Answer to the DEBATE? *J Endovasc Ther*. 2014 Feb;21(1):9-11.

Laird JR, Jain A, Zeller T, Feldman R, Scheinert D, Popma JJ, Armstrong EJ, Jaff MR. Nitinol Stent Implantation in the Superficial Femoral Artery and Proximal Popliteal Artery: 12 Month Results From the Complete SE Trial. *J Endovasc Ther*. 2014 Apr;21(2):202-12.

© 2017 UC Regents